Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02692105 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Comparison of HDR vs. LDR Brachytherapy as Monotherapy for Intermediate Risk Prostate Cancer

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Completion date: Apr 2026 to Dec 2028v9
  2. Re-verified, no change to tracked fieldsv8
  3. Trial status: Recruiting to Active, Not Recruiting Primary completion date changed from estimate of Dec 2022 to Apr 2021 · Site details revisedv7 Show 2 more changesShow less
    • Primary completion date changed from estimate of Dec 2022 to Apr 2021
    • Site details revised
  4. Primary completion date: May 2021 to Dec 2022v6
  5. Primary completion date: Apr 2018 to May 2021v5
Show 3 earlier versionsHide 3 earlier versions
  1. 2 versions Re-verified since Jul 14, 2017, no change to tracked fieldsv3-v4
  2. Trial status: Not Yet Recruiting to Recruiting Start date: Apr 2016 to May 2016 · Site details revisedv2 Show 2 more changesShow less
    • Start date: Apr 2016 to May 2016
    • Site details revised
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will offer men with intermediate risk prostate cancer who are suitable for, and interested in, prostate brachytherapy, the opportunity to be randomized between low dose rate (LDR) brachytherapy using permanent implantation of radioactive seeds (the current standard of care in BC) and high dose rate (HDR) or temporary brachytherapy which is also available as a standard of care in BC but only when used as a boost in addition with external beam radiotherapy. In addition, men will be offered the opportunity for testing the aggressiveness of their cancer using Cell Cycle Progression Gene Profile.
Trial Details
NCT Number NCT02692105
Lead Sponsor British Columbia Cancer Agency
Conditions Prostate Cancer
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov